Bioventix PLC (LON:BVXP - Get Free Report) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 2,620.16 ($34.52) and traded as high as GBX 2,890 ($38.08). Bioventix shares last traded at GBX 2,878 ($37.92), with a volume of 5,484 shares trading hands.
Bioventix Stock Performance
The company has a 50-day simple moving average of GBX 2,620.16 and a 200-day simple moving average of GBX 3,083.28. The stock has a market cap of £150.70 million, a P/E ratio of 18.61 and a beta of 0.35.
Bioventix (LON:BVXP - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.95) earnings per share (EPS) for the quarter. Bioventix had a return on equity of 69.09% and a net margin of 59.51%. As a group, sell-side analysts expect that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.
Bioventix Cuts Dividend
The firm also recently disclosed a dividend, which was paid on Friday, April 25th. Shareholders of record on Thursday, April 10th were given a GBX 70 ($0.92) dividend. The ex-dividend date of this dividend was Thursday, April 10th. This represents a yield of 2.95%. Bioventix's payout ratio is 102.19%.
Insider Buying and Selling at Bioventix
In other news, insider Bruce Hiscock bought 31 shares of the stock in a transaction dated Monday, April 28th. The stock was bought at an average cost of GBX 2,632 ($34.68) per share, with a total value of £815.92 ($1,074.99). Corporate insiders own 8.02% of the company's stock.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
